BeOne Medicines (ONC) Cost of Revenue (2017 - 2026)

BeOne Medicines (ONC) has 10 years of Cost of Revenue data on file, last reported at $167.2 million in Q1 2026.

• On a quarterly basis, Cost of Revenue rose 1.34% year-over-year to $167.2 million in Q1 2026; TTM through Mar 2026 was $670.8 million, a 5.77% increase from a year earlier, with the FY2025 full-year figure at $668.5 million, up 12.53% from the prior year.
• Cost of Revenue for Q1 2026 stood at $167.2 million, up from $142.4 million in the prior quarter.
• Over the last five years, Cost of Revenue for ONC reached as high as $196.5 million in Q3 2025 and fell as low as $65.2 million in Q1 2022.
• Historically, Cost of Revenue has averaged $123.3 million across 5 years, with a median of $124.9 million in 2024.
• Across the five-year window, Cost of Revenue jumped 99.59% in 2022 and decreased 11.3% in 2025, its largest moves.
• Year by year, Cost of Revenue stood at $73.5 million in 2022, then jumped by 43.95% to $105.8 million in 2023, then jumped by 51.71% to $160.6 million in 2024, then retreated by 11.3% to $142.4 million in 2025, then climbed by 17.41% to $167.2 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $167.2 million in Q1 2026, $142.4 million in Q4 2025, and $196.5 million in Q3 2025.